Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


PCR (polymerase chain reaction) alternatives will drive NAT (Nucleic Acid Testing) growth to 2006

This article was originally published in Clinica

Executive Summary

Most new products arriving on the Nucleic Acid Testing (NAT) market do not utilise the polymerase chain reaction (PCR). Instead, they make use of isothermal amplification technologies to achieve the high sensitivities often required for applications such as infectious disease testing. Unlike the currently dominant PCR technique, these new methods no longer require thermal cycling. This means that instrumentation and assay protocols can be greatly simplified. Other products set to impact the market over the next few years use technologies which amplify the test signal, and not the target nucleic acid as PCR does. By amplifying the assay label, many problems associated with sample contamination and carryover can be reduced or eliminated. In addition, other products are incorporating novel methods for increasing assay sensitivity that do not require nucleic acid amplification at all.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts